Dean Diagnoses Layouts Next-Generation Precision Medicine Creates World-Class Third-Party Laboratories

Medical Network June 26th Recently, the Swiss Roche Group and the American Foundation Medicine Company announced that they have reached a merger agreement to further accelerate the accelerated development of personalized medicine, and promote comprehensive genome sequencing analysis (CGP) and innovative data services. Securities Times reporter learned that as a cooperative partner of Roche and FMI, Dean Diagnostics (300244) is actively promoting the deepening of the tripartite cooperation project in China, allowing Chinese patients to benefit from the global leading cancer comprehensive genome sequencing analysis technology as soon as possible.

On June 19th, the global biotechnology giant Roche Group announced that it has reached an M&A agreement with FMI, the world's leading molecular information technology company. The Roche Group acquired the remaining FMI's outstanding shares for US$2.4 billion on a 56% basis in the previous period. .

'Deja vu', this is the feeling of this acquisition to Chen Haibin, chairman of Dean Diagnostics. The Roche Group has successively made industrial arrangements through step-by-step acquisitions, such as the acquisition of Genentech, the founder of the biotechnology industry. , Work together to promote the development of related fields, and wait until the market matures to complete a wholly-owned acquisition. 'Nearly second generation sequencing technology (NGS) approach similar to the first investment in shares in FMI, after the general trend of wholly-owned acquisitions. Grasp the strategic core, accurate judgments Industry trends, the strategic measures of both cultivation and development are reflected in the Roche Group.

Roche Group's molecular information technology can be traced back to three years ago. In January 2015, Roche Group announced the acquisition of 56% of FMI for US$1.03 billion and acquired an overall valuation of US$1.86 billion. In June 2018, Roche spent 2.4 billion. The US dollar acquired all the outstanding shares of FMI and acquired an overall valuation of 5.3 billion U.S. dollars.

From development medical instruments proxy Since the start of business, Dean Diagnostics and the Roche Group have been on the road of cooperation for 22 years. The Roche Group is not only the most important partner in business, but also a good friend and teacher of Dean Diagnostic Development.

Even more noteworthy is that in April this year, Dean Diagnostics signed a related agreement with Roche Group, FMI, which agreed that Dean would establish Dean's exclusive authorization in the Chinese market by acquiring FMI's comprehensive genome sequencing and analysis of relevant technologies in the Chinese market. Cancer Precision Diagnostics Laboratory. When the Roche Group announced a wholly-owned acquisition of FMI, a number of Dean diagnostic technicians were in the laboratory of FMI USA and Germany.

' Dean is really at the forefront of the industry. ' Liu Jianyun, technical director of Dean's Oncology Precision Diagnostic Laboratory, said, 'Now, the number of samples in Dean's Hangzhou Laboratory and FMI's German Laboratory is similar. In the early stages of project cooperation, we will do our best. It is possible to use manual operations to screen and reserve a group of technicians who meet the standards of NGS technology.

Chen Haibin stated that the three-level goal (learning, collaboration, innovation) is the initial focus of Dean Diagnostics's FMI, which is to learn the world's new technologies, new models, and develop collaboratively with the world's medical channels, realize data sharing, and prepare for independent research and innovation.

It is understood that FMI's FoundationOneCDxTM has been approved by the FDA as the first clinically validated NGS companion diagnosis (CDx) in 2017. According to the tripartite protocol of Roche, FMI and Dean Diagnostics, Dean Diagnostics has become a full genome sequencing analysis of FMI tumors. The exclusive partner of technology in the Chinese market, Roche Group will work with Dean Diagnostics to promote the commercialization of these products in the Chinese clinical market.

Dean Diagnostics stated that the tripartite cooperation is proceeding in an orderly manner and has now entered a substantive stage of implementation.

Prior to this, the dispatch training for Dean diagnostic technicians was also in full swing. Dean's diagnosis told reporters that in the nearly one month's training and study time, the company's technical staff has been able to independently analyze 20 clinical samples every day. For Chen Haibin, Chairman of the Board of Directors, these technical backbones are the 'Dean's diagnostics, a group of craftsmen who learn from the industry giants about their cutting-edge technologies.'

The reporter learned that in addition to expatriate training, the second half of the year will be officially completed and run. In addition, FMI experts will be invited to Dean's laboratory for on-site testing, technical support, and verification to ensure that FMI products are China's operation can be global standard Equivalent.

Chen Haibin said that Dean Diagnostics has cooperated with Roche Group for more than 20 years. It is not only the evolution of the company's iterative upgrade, but also the process of team learning and evolution. Cooperation with FMI will lead Dean Diagnostics to master the core technologies of NGS product testing and the world's leading Standardized procedures lay the foundation for Dean's diagnosis to build a world-class third-party laboratory.